These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2360238)

  • 21. Evaluation of prophylactic replacement therapy in haemophilia B.
    Morfini M; Mannucci PM; Mariani G; Panicucci F; Petrucci F; Baicchi U; Capitanio A; Ferrini PL; Mandelli F
    Scand J Haematol; 1976 Jan; 16(1):41-7. PubMed ID: 1251139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)].
    Verroust F; Moussard C; Allain JP
    Presse Med; 1985 May; 14(19):1073-6. PubMed ID: 3158962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Christmas disease and Stuart-Prower deficiency with a prothrombin-complex concentrate (factors II, VII, IX, X).
    Tullis JL; Melin M
    Bibl Haematol; 1968; 29():1134-9. PubMed ID: 5700309
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of preparation PPSB on coagulation and hemostasis in hemophilia B patients].
    Tarasova LN; Sadkov SA; Porokhnenko SG
    Gematol Transfuziol; 1984 Aug; 29(8):22-4. PubMed ID: 6479558
    [No Abstract]   [Full Text] [Related]  

  • 26. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
    Ludwig E; Lechner K
    Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
    [No Abstract]   [Full Text] [Related]  

  • 27. Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
    He P; Zhang F; Zhong C; Li M; Zheng J; Hua B; Sun J
    Int J Hematol; 2019 Jul; 110(1):59-68. PubMed ID: 31006077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current management of hemophilia B: recommendations, complications and emerging issues.
    Franchini M
    Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemophilia B: current pharmacotherapy and future directions.
    Franchini M; Frattini F; Crestani S; Bonfanti C
    Expert Opin Pharmacother; 2012 Oct; 13(14):2053-63. PubMed ID: 22946758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
    Hansson KM; Lindblom A; Elg M; Lövgren A
    Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new treatment strategy for hemophilia B: incorporation of factor IX into red cell ghosts.
    Goldsmith JC; Roer ME; Orringer EP
    Am J Hematol; 1979; 7(2):119-25. PubMed ID: 539589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor.
    Lowe GD; Harvie A; Forbes CD; Prentice CR
    Br Med J; 1976 Nov; 2(6044):1110-1. PubMed ID: 990791
    [No Abstract]   [Full Text] [Related]  

  • 35. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
    Windyga J; Abbuehl BE; Hafeman AE
    Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.
    Hazendonk HCAM; Preijers T; Liesner R; Chowdary P; Hart D; Keeling D; Driessens MHE; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Mathôt RAA; Collins PW; Cnossen MH
    Haemophilia; 2018 Jul; 24(4):611-618. PubMed ID: 29707861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dental extractions and the use of Christmas factor concentrate in cases of haemophilia B.
    Van Creveld S; Buchner R
    Vox Sang; 1970 May; 18(5):441-9. PubMed ID: 5311512
    [No Abstract]   [Full Text] [Related]  

  • 38. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of Rixubis™ in the treatment of hemophilia B.
    Valentino LA
    Immunotherapy; 2014; 6(4):381-94. PubMed ID: 24815779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.